Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FONDACAST: Fondaparinux vs Nadroparin in Below-Knee Injury
NCT00843492Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2008
- Primary completion
- Jan 2010
- Modality
- Allosteric Modulators
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by GSK. Primary endpoint: Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization. Started Dec 2008; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00843492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843492.